Ipsen S.A. (IPSEF)

UPDATE 3-US FDA approves French drugmaker Ipsen's rare bone disorder drug

The U.S. Food and Drug Administration (FDA) on Wednesday approved French drugmaker Ipsen's drug for a rare bone disorder, making it the first treatment available to patients with the condition that causes abnormal bone growth. The company said its drug, Sohonos, was approved in adults and pediatric patients with fibrodysplasia ossificans progressiva (FOP), a rare genetic connective tissue disorder that causes progressive loss of mobility and reduced life expectancy.